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Introduction : Dobutamine remains gold-standard treatment in cardio-
genic shock. However, it exacerbates tachycardia, worsening heart failure.
Ivabradine, a specific inhibitor of If channel, could reduce this deleterious
effect in association with dobutamine in patients with cardiogenic shock.
We report the case of a 41-year-old woman admitted in intensive care unit
for a severe heart failure with hemodynamic shock. She had no medical
history.
She suffered from thoracic and epigastric pain and cholecystis was initially
diagnosed with an indication of sphincterotomy. However, her clinical status
progressively worsened with severe dyspnea and global heart failure requiring
appropriate treatment. ECG showed inverted T waves in the lateral leads and
echocardiography showed a dilated cardiomyopathy with severe systolic alter-
ation (LVEF: 35%). Coronary angiogram was strictly normal. Finally, no evi-
dence was found on cardiac MRI for ischemic process or myocarditis. She
progressively worsened with renal and hepatic dysfunction. Troponin and
inflammation markers remained negative. It was necessary to introduce
dobutamine and intravenous diuretics but we noticed an initial increase in
heart rate concomitantly with blood pressure. We added ivabradine in order to
reduce heart rate without effect on blood pressure (fig). Her clinical status
improved and dobutamine could be stopped after 5 days and beta-blockers
were then introduced.
Discussion: Heart rate is a well-known marker of prognosis and tachy-
cardia worsened by dobutamine could be deleterious to evolution of patient
with cardiogenic shock. Ivabradine could be helpful in reducing heart rate
without effect on blood pressure. However, this drug is indicated in stable
heart failure but, to this day, hemodynamic instability is excluded. New pro-
spective studies seem necessary to evaluate this benefit.
Conclusion: In cardiogenic shock, association of dobutamine and ivabra-
dine could be interesting to create a pure inotropic drug.
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Objective: To determine the value, limitations and complications of throm-
bolysis in pulmonary embolism.
Patients and methods: This is a descriptive study of all patients admitted to
the cardiology department of CHU Ibn Rushd from 2009 to 2011 with pulmo-
nary embolism confirmed by echocardiography and chest CT angiography.
Result: these 68 patients with a mean age of 49 months or over 19 years
with a female.
The styles of pulmonary embolism vary widely with the management is
different.
5% of patients with pulmonary embolism occurs in cardiac arrest and
fibrinolysis offers better benefits and has no indication cons.
10 to 20% of pulmonary embolism with hemodynamic instability occurs
PAS ≤ 90 mmHg or respiratory distress Quick Installation fibrinolysis in these
patients provides better clinical improvement and ultrasound.
Pulmonary embolism at low risk and intermediate risk shows no indication
for fibrinolysis using simple anticoagulation. The rate of cerebral hemorrhage
is zero, 5 cases of gastrointestinal bleeding under control, intra-hospital
overall mortality is about 7%. 
Conclusion: This series demonstrates the value of thrombolysis on the dis-
solution of stones in the pulmonary arteries and hemodynamic parameters as
well as the reduction in mortality despite the slight increased risk of bleeding.
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Bleeding is the major complication of anticoagulant therapy. The criteria to
define the severity of bleeding varies considerably between studies, depending
on the variation in rates of bleeding reported. They depend on the intensity of
anticoagulant effect, patient characteristics and duration of treatment.
Objective: The aim of our study is to investigate the epidemiological, clin-
ical and evolution of 80 cases of hemorrhagic stroke with variable severity
collected at the cardiology department of the University Hospital Ibn Rushd
of Casablanca.
Results: The average age of our patients was 46.17 years, with a 62%
female predominancy. The indications of anticoagulant therapy were: the
atrial fibrillation in 60% of cases, a mechanical prosthesis in 20% of cases.
Bleeding is manifested by gastrointestinal bleeding in 30% of patients, rectal
bleeding in 20% of cases, gingival bleeding in 18% of cases, haematuria in
15% of cases, bruising of the soft tissues in 10% of cases, and a hematoma of
floor of mouth in 2% of cases. Patients received transfusions of packed red
blood cells and fresh frozen plasma with clinical and biological improvement.
Conclusion: The risk of bleeding under oral anticoagulation cannot be
considered in isolation, the potential decrease in thromboembolic phenomenon
must be balanced versus the potential increased risk of bleeding.
